Eyepoint, Inc.
A biopharmaceutical company that treats serious eye diseases with tiny, long-lasting implants placed in the eye. Its Durasert technology delivers steady doses of medication over months, powering products like YUTIQ for uveitis and DEXYCU for inflammation after cataract surgery. Founded in 1987 and long known as pSivida Corporation, it renamed itself EyePoint in 2018 after buying Icon Bioscience — the name a nod to its single-minded focus on the eye.
Sold 247.3K
Bought 4.79M · Sold 60.0K
Granted 330.5K · Bought 3.2K · Sold 65.0K
Granted 239.7K · Bought 1.5K
Granted 134.7K
Sold 2.91M
Sold 2.91M
Granted 197.8K · Sold 121.3K
Granted 98.4K · Sold 73.2K
Granted 4.0K · Bought 32.5K
Granted 10.0K
Granted 60.3K · Sold 46.0K
Granted 29.3K · Sold 34.9K
Bought 5.0K
Bought 2.6K
Granted 2.0K
Granted 56.2K · Sold 52.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| EW Healthcare Partners, L.P. +3 co-filers10% owner, See footnotes 1 and 3, 10% owner · 7 transactions | — | 14.68Mas of Sep 2023 | — | — | 247.3K |
| Chen Bihua +2 co-filersFormer 10% Owner · 25 transactions | — | 8.27M | — | 4.79M | 60.0K |
| Lurker NancyDirector · 24 transactions | — | 421.2K | 330.5K | 3.2K | 65.0K |
| Duker Jay S.President and CEO, Director · 31 transactions | — | 356.8K | 239.7K | 1.5K | — |
| Elston GeorgeChief Financial Officer · 33 transactions | — | 240.3K | 134.7K | — | — |
| Liu YeDirector · 3 transactions | -96.7% | 100.2Kas of Jan 2024 | — | — | 2.91M |
| Ocumension TherapeuticsDirector · 3 transactions | -96.7% | 100.2Kas of Jan 2024 | — | — | 2.91M |
| Paggiarino Dario A.Chief Medical Officer · 36 transactions | +188.5% | 74.2Kas of Mar 2024 | 197.8K | — | 121.3K |
| Jones David ScottSVP & Chief Commercial Officer · 28 transactions | +93.3% | 48.6Kas of Feb 2024 | 98.4K | — | 73.2K |
| Zaderej Karen L.Director · 7 transactions | +1825% | 38.5Kas of Jul 2025 | 4.0K | 32.5K | — |
| Landis John B.Director · 1 transaction | +87.7% | 21.4Kas of Jan 2025 | 10.0K | — | — |
| Pine Michael CraigChief Corp Dev.&Strat. Officer · 5 transactions | +1266.2% | 13.7Kas of Jan 2024 | 60.3K | — | 46.0K |
| Guyer David RDirector · 9 transactions | +82.1% | 13.5Kas of Jul 2024 | 29.3K | — | 34.9K |
| Ando GoranDirector · 1 transaction | +61.3% | 13.2Kas of Aug 2024 | — | 5.0K | — |
| Dicicco Wendy FDirector · 1 transaction | +34.7% | 10.0Kas of Aug 2024 | — | 2.6K | — |
| Adamis Anthony PDirector · 1 transaction | +100% | 4.0Kas of Jun 2024 | 2.0K | — | — |
| Ribeiro RamiroChief Medical Officer · 11 transactions | — | 2.4K | 56.2K | — | 52.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -1.68M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.